Myeloma Update

ABSTRACT

Myeloma is the most common primary bone malignancy and one of the most common hematologic malignancies. Research on myeloma constantly produces new information on genetic factors, imaging techniques, and treatment complications among others that is of use to patients, referring physicians, and radiologists. This update emphasizes new developments regarding imaging techniques for diagnosis, staging, and follow-up of myeloma patients. Advances in whole body radiography, whole body computed tomography, whole body magnetic resonance imaging, and whole body nuclear techniques (including sestamibi and positron emission tomography) are discussed.

KEYWORDS

Myeloma - imaging - computed tomography - magnetic resonance imaging - positron emission tomography

REFERENCES

• 1 Alexander D D, Mink P J, Adami H O et al.. Multiple myeloma: a review of the epidemiologic literature.  Int J Cancer. 2007;  120(Suppl 12) 40-61
• 2 Corre J, Mahtouk K, Attal M et al.. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.  Leukemia. 2007;  21 1079-1088
• 3 Shaughnessy J D, Haessler J, van Rhee F et al.. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.  Br J Haematol. 2007;  137 530-536
• 4 Tinguely M, Jenni B, Reineke T et al.. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.  Am J Surg Pathol. 2007;  31 690-696
• 5 International Myeloma Working Group . Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders.  Br J Haematol. 2003;  121 749-757
• 6 Greipp P R, San Miguel J, Durie B G et al.. International staging system for multiple myeloma.  J Clin Oncol. 2005;  23 3412-3420
• 7 Mulligan M E. Imaging techniques used in the diagnosis, staging, and follow-up of patients with myeloma.  Acta Radiol. 2005;  46 716-724
• 8 Durie B G, Salmon S E. A clinical staging system for multiple myeloma.  Cancer. 1975;  36 842-854
• 9 Durie B G, Kyle R A, Belch A et al.. Myeloma management guidelines: a consensus report from the scientific advisors of the international myeloma foundation.  Hematol J. 2003;  4 379-398
• 10 Moulopoulos L A, Maris T G, Papanikolaou N, Panagi G, Vlahos L, Dimopoulos M A. Detection of malignant bone marrow involvement with dynamic contrast-enhanced magnetic resonance imaging.  Ann Oncol. 2003;  14 152-158
• 11 Walker R, Barlogie B, Haessler J et al.. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.  J Clin Oncol. 2007;  25 1121-1128
• 12 Durie B G, Waxman A D, D'Agnolo A, Williams C M. Whole-body 18F-FDG PET identifies high-risk myeloma.  J Nucl Med. 2002;  43 1457-1463
• 13 Gertz M A. Relevant prognostic features of multiple myeloma and the new international staging system.  Leuk Lymphoma. 2007;  48 458-468
• 14 Moulopoulos L A, Dimopoulos M A, Weber D, Fuller L, Libshitz H I, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone.  J Clin Oncol. 1993;  11 1311-1315
• 15 Mulligan M E. Myeloma and lymphoma.  Semin Musculoskelet Radiol. 2000;  4 127-135
• 16 Tsang R W, Gospodarowicz M K, Pintilie M et al.. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome.  Int J Radiat Oncol Biol Phys. 2001;  50 113-120
• 17 Ooi G C, Chim J C, Au W Y, Khong P L. Radiologic manifestations of primary solitary extramedullary and multiple solitary plasmacytomas.  AJR Am J Roentgenol. 2006;  186 821-827
• 18 Weber D M, Dimopoulos M A, Moulopoulos L A, Delasalle K B, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma.  Br J Haematol. 1997;  97 810-814
• 19 Blade J, Rosinol L. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.  Curr Treat Options Oncol. 2006;  7 237-245
• 20 Mulligan M E, Badros A Z. PET/CT and MR imaging in myeloma.  Skeletal Radiol. 2007;  36 5-16
• 21 Dispenzieri A. POEMS syndrome.  Hematol Am Soc Hematol Educ Program. 2005;  360-367
• 22 Horger M, Claussen C, Bross-Bach U et al.. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography.  Eur J Radiol. 2005;  54 289-297
• 23 Mahnken A H, Wildberger J E, Gehbauer G et al.. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography.  AJR Am J Roentgenol. 2002;  178 1429-1436
• 24 Durie B G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon PLUS staging system.  Eur J Cancer. 2006;  42 1539-1543
• 25 Hillengass J, Wasser K, Delorme S et al.. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.  Clin Cancer Res. 2007;  13 475-481
• 26 Lecouvet F E, Dechambre S, Malghem J, Ferrant A, Vande Berg B C, Maldague B. Bone marrow transplantation in patients with multiple myeloma: prognostic significance of MR imaging.  AJR Am J Roentgenol. 2001;  176 91-96
• 27 Breyer R J, Mulligan M E, Smith S E, Line B R, Badros A Z. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma.  Skeletal Radiol. 2006;  35 632-640
• 28 Bredella M A, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma.  AJR Am J Roentgenol. 2005;  184 1199-1204
• 29 Agool A, Schot B, Jager P, Vellenga E. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment.  J Nucl Med. 2006;  47 1592-1598
• 30 Dankerl A, Liebisch P, Glatting G et al.. Multiple myeloma: molecular imaging with 11C-methionine PET/CT-initial experience.  Radiology. 2007;  242 498-508
• 31 Nanni C, Zamagni E, Cavo M et al.. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.  World J Surg Oncol. 2007;  5 68-75
• 32 Mele A, Offidani M, Visani G et al.. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans.  Br J Haematol. 2007;  136 729-735
• 33 Durie B G, Harousseau J L, Miguel J et al.. International uniform response criteria for multiple myeloma.  Leukemia. 2006;  20 1467-1473
• 34 Badros A, Weikel D, Salama A et al.. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.  J Clin Oncol. 2006;  24 945-952
• 35 Lacy M Q, Dispenzieri A, Gertz M A et al.. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma.  Mayo Clin Proc. 2006;  81 1047-1053